India's Hep-C Market: The Old Order Changeth?
This article was originally published in Scrip
Is peginterferon alfa 2b potentially heading for near obsolescence on the Indian market as a therapy for hepatitis C virus (HCV) infection, now with the availability of cut-price sofosbuvir versions? Probably yes, if a clutch of industry pundits are to be believed and going by some market-related activity or indeed the lack of it.
Register for our free email digests: